Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

The US regulator issued a complete response letter (CRL) for the MedinCell-partnered drug, and the companies haven't been forthcoming on the reasons behind the rejection, saying merely that they ...

Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that ...

Compass Pathways plc , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the TD Cowen 45th ...

Futura Medical plc research, develops, and sells pharmaceutical and healthcare products for sexual health. Its lead product is Eroxon, a topical gel for the treatment of erectile dysfunction.

SAE Media Group's 15th Annual Pre-Filled Syringes and Injectable Drug Devices Conference 2023 will be bigger than ever, with a pre-conference focus day exploring the advances in PFS design for ...